New hope for Late-Stroke patients: drug trial uses advanced imaging to guide treatment

NCT ID NCT07379190

Recruiting now Disease control Sponsor: Weifang Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether the drug tirofiban can help people who have had a stroke but missed the usual treatment window (more than 24 hours after symptoms start). The study uses a special MRI scan to select patients whose stroke is caused by a specific type of artery blockage. 458 participants will receive either tirofiban or standard anti-clot drugs, and researchers will measure how well they recover over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirofiban
What this could lead to: If successful, this could provide a new treatment option for stroke patients who miss the standard treatment window, potentially improving their recovery and reducing disability.
What could go wrong: This is a Phase 3 trial, but it's still early to know if tirofiban is truly better than standard care. There is a risk of bleeding, and the results may not apply to all stroke types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO INTRACRANIAL LARGE-ARTERY ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral infarction intracranial arteriosclerosis ischemic stroke large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CEREBRAL INFARCTION STROKE, ACUTE STROKE, ISCHEMIC

Contacts and locations

Locations

Weifang People's Hospital
RECRUITING

Weifang, China/Shandong Province, 261000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.